Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series

Ruggero De Maria Marchiano, Luigi Di Lauro, Patrizia Vici, Maddalena Barba, Laura Pizzuti, Domenico Sergi, Massimo Rinaldi, Anna Di Benedetto, Isabella Sperduti, Abeer M. Shaaban, Valerie Speirs, Marcella Mottolese, Marcello Maugeri-Saccà

Risultato della ricerca: Contributo in rivistaArticolo in rivista

20 Citazioni (Scopus)

Abstract

Male breast cancer is a rare disease treated as hormone receptor-positive female breast cancer. The characterization of breast cancer at the molecular level has lately revealed gender-related differences. As the androgen receptor is emerging as a potential oncogenic driver in male breast cancer, we analyzed efficacy data from metastatic patients treated with antiandrogens. We evaluated the activity of cyproterone acetate, either as a monotherapy or combined with a GnRH analog, in 36 metastatic male breast cancer patients. Fourteen patients were treated with cyproterone acetate as monotherapy and 22 patients with complete androgen blockade. We recorded 4 complete responses and 15 partial responses, for an overall response rate of 52.8 % (95 % CI, 36.5–69.4). Stable disease was reported in 11 patients. Median PFS was 8.9 months (95 % CI, 6.1–11.7), and median OS was 24.3 months (95 % CI, 22.5–26.1). Data on androgen receptor expression were available for 7 patients. All the 4 patients with androgen receptor-expressing tumors had a clinical benefit, including a patient with an estrogen receptor-negative disease. Conversely, none of the 3 patients with androgen receptor-negative tumors had a tumor response. Antiandrogen-based therapy showed efficacy in metastatic male breast cancer patients. Our results encourage considering antiandrogens in the therapeutic continuum, especially if supported by androgen receptor expression.
Lingua originaleEnglish
pagine (da-a)73-80
Numero di pagine8
RivistaBreast Cancer Research and Treatment
Volume148
DOI
Stato di pubblicazionePubblicato - 2014

Keywords

  • Adult
  • Aged
  • Androgen Antagonists
  • Androgen receptor
  • Antiandrogens
  • Antineoplastic Agents, Hormonal
  • Breast Neoplasms, Male
  • Cancer Research
  • Cyproterone Acetate
  • Cyproterone acetate
  • Disease-Free Survival
  • GnRH analogs
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Metastatic male breast cancer
  • Middle Aged
  • Oncology
  • Receptors, Androgen
  • Retrospective Studies
  • Treatment Outcome

Fingerprint

Entra nei temi di ricerca di 'Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series'. Insieme formano una fingerprint unica.

Cita questo